CIBC World Market’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$12.9M Sell
84,313
-444,250
-84% -$68.1M 0.02% 337
2025
Q4
$72.9M Buy
528,563
+374,016
+242% +$49M 0.12% 119
2025
Q3
$19.8M Sell
154,547
-4,451
-3% -$543K 0.04% 271
2025
Q2
$19.2M Sell
158,998
-1,704,000
-91% -$192M 0.04% 261
2025
Q1
$208M Buy
1,862,998
+1,813,497
+3,664% +$193M 0.44% 52
2024
Q4
$4.82M Buy
49,501
+453
+0.9% +$48.3K 0.01% 524
2024
Q3
$5.64M Sell
49,048
-209
-0.4% -$23.7K 0.01% 457
2024
Q2
$5.24M Sell
49,257
-1,512
-3% -$152K 0.01% 434
2024
Q1
$4.91M Sell
50,769
-2,411
-5% -$247K 0.01% 459
2023
Q4
$5.37M Sell
53,180
-63,100
-54% -$6.09M 0.01% 393
2023
Q3
$11.2M Sell
116,280
-14,270
-11% -$1.45M 0.04% 222
2023
Q2
$13.2M Buy
130,550
+614
+0.5% +$61.4K 0.04% 215
2023
Q1
$12M Sell
129,936
-1,642
-1% -$143K 0.04% 228
2022
Q4
$11.9M Buy
131,578
+54
+0% +$4.55K 0.04% 231
2022
Q3
$10M Sell
131,524
-3,852
-3% -$319K 0.04% 232
2022
Q2
$11.4M Sell
135,376
-1,188
-0.9% -$104K 0.04% 219
2022
Q1
$12M Sell
136,564
-12,093
-8% -$1.05M 0.04% 222
2021
Q4
$13M Buy
148,657
+237
+0.2% +$19.7K 0.04% 224
2021
Q3
$12.1M Sell
148,420
-918
-0.6% -$82.6K 0.04% 217
2021
Q2
$13.6M Buy
149,338
+4,975
+3% +$443K 0.04% 216
2021
Q1
$12.3M Buy
144,363
+4,096
+3% +$368K 0.04% 218
2020
Q4
$13.2M Buy
140,267
+21,470
+18% +$1.88M 0.04% 206
2020
Q3
$10.3M Buy
118,797
+8,538
+8% +$740K 0.04% 203
2020
Q2
$9.63M Buy
110,259
+4,473
+4% +$386K 0.04% 200
2020
Q1
$8.72M Buy
105,786
+34,173
+48% +$3.05M 0.04% 185
2019
Q4
$6.78M Buy
71,613
+3,299
+5% +$296K 0.03% 259
2019
Q3
$5.94M Buy
68,314
+1,022
+2% +$91.8K 0.03% 272
2019
Q2
$6.14M Sell
67,292
-3,885
-5% -$329K 0.03% 253
2019
Q1
$5.39M Sell
71,177
-48,772
-41% -$3.92M 0.02% 280
2018
Q4
$9.22M Sell
119,949
-2,035
-2% -$158K 0.05% 192
2018
Q3
$9.42M Sell
121,984
-1,600
-1% -$118K 0.04% 199
2018
Q2
$8.37M Buy
123,584
+25,094
+25% +$1.73M 0.04% 212
2018
Q1
$7.13M Buy
98,490
+60,835
+162% +$4.63M 0.03% 228
2017
Q4
$2.83M Buy
37,655
+6,610
+21% +$499K 0.01% 258
2017
Q3
$2.39M Sell
31,045
-84,523
-73% -$6.38M 0.01% 267
2017
Q2
$8.64M Buy
115,568
+47,626
+70% +$3.38M 0.04% 219
2017
Q1
$4.52M Sell
67,942
-38,033
-36% -$2.53M 0.01% 287
2016
Q4
$6.92M Buy
105,975
+45,723
+76% +$2.97M 0.02% 190
2016
Q3
$4.26M Buy
60,252
+15,818
+36% +$1.15M 0.02% 226
2016
Q2
$3.29M Buy
44,434
+27,860
+168% +$1.92M 0.01% 250
2016
Q1
$1.08M Sell
16,574
-10,824
-40% -$736K 0.01% 429
2015
Q4
$2.11M Buy
27,398
+7,081
+35% +$563K 0.01% 324
2015
Q3
$1.67M Sell
20,317
-4,593
-18% -$409K 0.01% 342
2015
Q2
$2.19M Buy
24,910
+6,402
+35% +$587K 0.01% 321
2015
Q1
$1.64M Buy
18,508
+12,354
+201% +$1.1M 0.01% 341
2014
Q4
$511K Sell
6,154
-76
-1% -$6.3K ﹤0.01% 599
2014
Q3
$525K Buy
6,230
+1,725
+38% +$140K ﹤0.01% 545
2014
Q2
$365K Buy
4,505
+67
+2% +$5.27K ﹤0.01% 586
2014
Q1
$338K Sell
4,438
-44
-1% -$3.21K ﹤0.01% 613
2013
Q4
$323K Buy
4,482
+325
+8% +$22.6K ﹤0.01% 587
2013
Q3
$286K Buy
4,157
+907
+28% +$60K ﹤0.01% 547
2013
Q2
$206K Buy
+3,250
New +$211K ﹤0.01% 541

Other funds holding NVS

CIBC World Market's NVS Position: Q1 2026 in Review

CIBC World Market reduced its Novartis (NVS) stake by 84% in Q1 2026, selling an estimated $68.1M and leaving 84,313 shares worth $12.9M. The position accounts for 0.02% of the portfolio, ranked #337.

CIBC World Market first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $208M in Q1 2025. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • CIBC World Market held 84,313 shares of Novartis worth $12.9M as of Q1 2026.
  • CIBC World Market sold 444,250 Novartis shares in Q1 2026, an estimated $68.1M.
  • Novartis made up 0.02% of CIBC World Market's portfolio in Q1 2026, its #337 holding.
  • CIBC World Market first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • CIBC World Market's Novartis position peaked at $208M in Q1 2025.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on CIBC World Market's 13F filing for Q1 2026, filed 14 May 2026.